1. MAPK/ERK Pathway
  2. MEK

MEK

MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK). The activators of p38 (MKK3 and MKK6), JNK (MKK4 and MKK7), and ERK (MEK1 and MEK2) define independent MAP kinase signal transduction pathways. The acronym MEK derives from Mitogen/Extracellular signal-regulated Kinase. MEK is a member of the MAPK signaling cascade that is activated in melanoma. When MEK is inhibited, cell proliferation is blocked and apoptosis (controlled cell death) is induced.

MEK Related Products (33):

Cat. No. Product Name Effect Purity
  • HY-12031
    U0126 Inhibitor 98.03%
    U0126 is a non-ATP competitive MEK inhibitor, with IC50 of 70 nM and 60 nM for MEK1 and MEK2, respectively.
  • HY-10999
    Trametinib Inhibitor 99.37%
    Trametinib is a potent MEK inhibitor that specifically inhibits MEK1/2, with an IC50 value of about 2 nM. Due to the poor solubility of Trametinib, Trametinib DMSO solvate (Cat. No.: HY-10999A) is the more commonly used form.
  • HY-12028
    PD98059 Inhibitor 99.45%
    PD98059 is a MEK inhibitor with IC50 of 5 μM, also suppresses TCDD binding to the aryl hydrocarbon receptor (AHR) with IC50 of 4 μM.
  • HY-10254
    PD0325901 Inhibitor 99.95%
    PD0325901 is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2.
  • HY-50706
    Selumetinib Inhibitor 99.39%
    Selumetinib is a highly potent MEK inhibitor, with an IC50 value of 14 nM against MEK1.
  • HY-19700
    trans-Zeatin Inhibitor 99.28%
    trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; also inhibits UV-induced MEK/ERK activation.
  • HY-13064
    Cobimetinib Inhibitor 99.38%
    Cobimetinib is a novel selective MEK inhibitor, and the IC50 value against MEK1 is 4.2 nM.
  • HY-10999A
    Trametinib DMSO solvate Inhibitor 99.69%
    Trametinib DMSO solvate is a potent MEK inhibitor that specifically inhibits MEK1/2, with an IC50 value of about 2 nM.
  • HY-15202
    MEK162 Inhibitor 98.61%
    MEK162 is a potent and selective mitogen-activated protein kinase (MEK) inhibitor wirh IC50 of 12 nM.
  • HY-50295
    CI-1040 Inhibitor 98.54%
    CI-1040 (PD184352) is an orally active, highly specific, small-molecule inhibitor of MEK with an IC50 of 17 nM for MEK1.
  • HY-12042
    AS703026 Inhibitor
    AS703026 is a highly selective, potent, ATP non-competitive allosteric inhibitor of MEK1/2, used for cancer treatment.
  • HY-100627
    APS-2-79 Antagonist 99.21%
    APS-2-79 behaves as a kinase suppressor of Ras (KSR)-dependent antagonist of RAF-mediated MEK phosphorylation. APS-2-79 binds directly to KSR2 within the KSR2-MEK1 complex with an IC 50 of 120±23 nM for KSR2.
  • HY-14691
    Refametinib Inhibitor 98.46%
    Refametinib is a potent, selective, allosteric MEK1/MEK2 inhibitor with IC50s of 19 nM and 47 nM, respectively.
  • HY-13449
    TAK-733 Inhibitor 99.74%
    TAK-733 is a potent and selective MEK allosteric site inhibitor with an IC50 of 3.2 nM.
  • HY-18652
    Ro 5126766 Inhibitor >98.0%
    Ro 5126766 is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAFV600E, CRAF, MEK, and BRAF (IC50: 8.2, 56, 160 nM, and 190 nM, respectively).
  • HY-12055
    BIX02188 Inhibitor 98.80%
    BIX02188 is a potent MEK5-selective inhibitor with an IC50 of 4.3 nM. BIX02188 inhibits ERK5 catalytic activity, with an IC50 of 810 nM.
  • HY-15504A
    RGB-286638 free base Inhibitor 99.55%
    RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, cyclin B1-CDK1, cyclin E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC50s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC50s of 3, 5, 50, and 54 nM.
  • HY-15437
    SL327 Inhibitor >98.0%
    SL327 inhibits MEK1 and MEK2, with IC50 values of 180 nM and 220 nM, respectively.
  • HY-12056
    BIX02189 Inhibitor 99.65%
    BIX02189 is a potent and selective MEK5 inhibitor with an IC50 of 1.5 nM. BIX02189 also inhibits ERK5 catalytic activity with an IC50 of 59 nM.
  • HY-15610
    GDC-0623 Inhibitor 98.71%
    GDC-0623 is a potent, ATP-uncompetitive inhibitor of MEK1 (Ki=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC50=42 nM) versus A375 (BRAFV600E, EC50=7 nM).